Targeting the spliceosome: A new therapeutic strategy to counteract chemotherapy resistance in lung cancer?

Rev Mal Respir. 2024 Mar 8:S0761-8425(24)00143-8. doi: 10.1016/j.rmr.2024.02.013. Online ahead of print.ABSTRACTLung cancer is the first cancer-related cause of death worldwide. This is in partially due to therapeutic resistance, which occurs in around 70% of patients, especially those receiving platinum salts, the gold-standard chemotherapy. The massive deregulation of alternative transcript splicing processes observed in many cancers has led to the development of a new class of pharmacological agents aimed at inhibiting the activity of the splicing machinery (spliceosome). The molecular mechanisms by which these inhibitors act remain largely unknown, as do the benefits of using them in combination with other therapies. In this context, our work is focused on an inhibitor of the SRPK1 kinase, a major regulator of the spliceosome.PMID:38461087 | DOI:10.1016/j.rmr.2024.02.013
Source: Revue des Maladies Respiratoires - Category: Respiratory Medicine Authors: Source Type: research